LLYEli Lilly
Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. 10-K, Item 1
- Employees
- 50,000
- Headquarters
- Indianapolis, IN
- CEO
- David A. Ricks
- Next results
- around Feb 3, 2027
Revenue, FY2016 to FY2025
$65.2B ▲ 44.7% in FY2025$20.6B ▲ 94.9% in FY2025
Each fiscal year from its 10-K. Every number, year by year →
9 new risk paragraphs and 3 accounting facts worth reading about
| Area | What changed | Source |
|---|---|---|
| Risk factors | 9 new paragraphs, nothing like them in the previous 10-K | 10-K Item 1A |
| Receivables growing faster than revenue | Receivables +61.4% vs revenue +44.7% (+16.7 pts) | 10-K · XBRL |
| Cash from operations lower than net income | Cash from operations $16.8B vs net income $20.6B (FY ending 2025-12-31) | 10-K · XBRL |
| Inventory growing faster than revenue | Inventory +81.1% vs revenue +44.7% (+36.4 pts) | 10-K · XBRL |
| Accounting checks | 8 other checks clear, 3 worth a look | 10-K · XBRL |
| Insiders | No open-market buys in the last 90 days | Form 4 |
| Filings | 2 in the last 30 days | EDGAR |
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
9 new paragraphs in Risk Factors, quoted as filed
Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-19. Quoted as filed.
In November 2025, we announced preliminary voluntary agreements with the U.S. government in which, among other arrangements, we agreed to implement measures to lower Medicaid and certain other drug prices for U.S. patients and to launch new medicines with a more balanced pricing approach across developed nations. We face risks and…
10-K, Item 1A
3 facts worth reading about, 8 checks with nothing to note
8 of 11 checks clear 3 worth a look. Checks, not verdicts.
- !Receivables growing faster than revenueReceivables +61.4% vs revenue +44.7% (+16.7 pts)
- !Cash from operations lower than net incomeCash from operations $16.8B vs net income $20.6B (FY ending 2025-12-31)
- !Inventory growing faster than revenueInventory +81.1% vs revenue +44.7% (+36.4 pts)
- ✓Same auditor in both 10-Ks: Ernst & Young LLP
- ✓No statement of substantial doubt about going concern
- ✓No 8-K item 4.02 in the last 2 years
- ✓No NT 10-K or NT 10-Q in the last 2 years
- ✓The same matters as last year: Medicaid, Managed Care, and Medicare sales rebate accruals
- ✓No sentence in the 10-K concludes that controls were not effective because of a material weakness
- ✓No 8-K item 2.06 in the last 2 years
- ✓No 8-K item 1.03 in the last 2 years
2 filings in the last 30 days
- Oct 29, 20268-K Quarterly results 8-K item 2.02
- Oct 29, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
Eli Lilly, Indianapolis, IN
Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment - human pharmaceutical products. Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
- Headquarters
- Indianapolis, IN
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Oct 29, 2026
- Incorporated in
- IN
Employees, at the top of the page: "At the end of 2025, we employed approximately 50,000 people, including approximately 27,000 employees outside the U" (10-K). Address and exchange: SEC's company file.
Permanent link, kept if the ticker changes: /c/sec:0000059478 (SEC's CIK).